

A seamless, Phase 1b/2 multiple ascending dose/proof of concept study of XTMA-16 in patients with pulmonary sarcoidosis with or without extrapulmonary manifestations

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- Diagnosis of pulmonary sarcoidosis with some respiratory symptoms - Must be taking 7.5 to 25 mg of prednisone daily and will to taper down dose - Must be on an additional medication for the treatment of sarcoidosis - Please contact umnsarc@umn.edu if you have any questions

Exclusion Criteria:

- Pregnancy or breast-feeding

Conditions & Interventions

Conditions:

Breathing, Lung & Sleep Health, Rare Diseases, Rare Diseases, Respiratory System

Keywords:

Clinics and Surgery Center (CSC), Sarcoidosis

More Information

Description: XTMA-16 is a new, experimental drug and is part of a group of drugs known as tumor necrosis factor alpha (TNF α) inhibitors. TNF is a protein in your body that causes inflammation. TNF α inhibitors work by suppressing part of the immune response along with reducing inflammation. We are conducting this research study to see if XTMA-16 will help in the treatment of pulmonary sarcoidosis.

Study Contact: Mandi DeGrote - carl1032@umn.edu

Principal Investigator: David Perlman

Phase: PHASE1

IRB

Number: STUDY00020802

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.